Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Accured Expenses: 2023-2024

Historic Change in Accured Expenses for Amylyx Pharmaceuticals (AMLX) over the last 2 years, with Dec 2024 value amounting to -$59.8 million.

  • Amylyx Pharmaceuticals' Change in Accured Expenses rose 108.35% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$31.8 million, marking a year-over-year decrease of 151.40%. This contributed to the annual value of -$59.8 million for FY2024, which is 376.94% down from last year.
  • Per Amylyx Pharmaceuticals' latest filing, its Change in Accured Expenses stood at -$59.8 million for FY2024, which was down 376.94% from $21.6 million recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Change in Accured Expenses registered a high of $21.6 million during FY2023, and its lowest value of -$59.8 million during FY2024.
  • Its 2-year average for Change in Accured Expenses is -$19.1 million, with a median of -$19.1 million in 2023.
  • Data for Amylyx Pharmaceuticals' Change in Accured Expenses shows a maximum YoY slumped of 376.94% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Amylyx Pharmaceuticals' Change in Accured Expenses stood at $21.6 million in 2023, then crashed by 376.94% to -$59.8 million in 2024.